Skip to main navigation

About
Pipeline
Patients
Investors
Contact Us

Investor Relations

Investors
Press Releases
Event Calendar
Stock Info
Governance
Financial Info
Shareholder Services
Presentations

Shareholder Tools

Facebook
Google
LinkedIn
Twitter

Press Releases

Keyword Search

Year

11/14/22

Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results

09/27/22

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

08/15/22

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results

05/12/22

Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference

05/11/22

Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results

03/31/22

Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results

01/10/22

Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

© 2022 Bellerophon Therapeutics. All rights reserved.

Site Map
Terms of Use
Privacy Policy